Emily Kimber

The US Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ Ajovy (fremanezumab-vfrm) to prevent episodic migraine in paediatric patients. The drug, which is already approved in the US to prevent migraine in adults, is now authorised for use in patients aged six to 17 years who weigh at least 45 kilograms. One in ten children and adolescents in the US are affected by migraine, a neurological condition that can cause pain, nausea, vomiting and sensitivities to light and sound.

Eli Lilly has shared positive top-line results from a late-stage study of its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist as a weight-loss treatment. The phase 3 ATTAIN-1 trial has been evaluating three once-daily doses of orforglipron in over 3,000 non-diabetic adults who were obese, or overweight with a weight-related medical problem.

Almirall and Absci Corporation have announced that they will be expanding their ongoing artificial intelligence (AI) drug discovery collaboration to include a second dermatology target selected by Almirall. The alliance, originally announced in November 2023, combines Almirall’s dermatological capabilities with Absci’s Integrated Drug Creation platform and has already led to the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target, the partners said.